Hikma Pharmaceuticals Plc Hikma Ventures- $20.5m Series C round for Prognos
November 30 2017 - 12:47PM
RNS Non-Regulatory
TIDMHIK
Hikma Pharmaceuticals Plc
30 November 2017
Hikma Ventures participates in a $20.5 million Series C round
for Prognos
London, 30 November 2017 - Hikma Pharmaceuticals PLC (Hikma)
(LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), (rated Ba1 Moody's /
BB+ S&P, both stable) announces that its venture capital arm,
Hikma International Ventures and Development LLC (Exempt) (Hikma
Ventures) has participated in a $20.5 million series C round of
financing for Prognos alongside Merck Global Health Innovation
Fund, Safeguard Scientifics, Guardian Health, Cigna, and other
investors.
Prognos leverages clinical diagnostic data and Artificial
Intelligence (AI) to develop advanced analytics solutions for the
payer, diagnostics, and life science markets. The Prognos Registry
of 13 billion clinical records for 180 million patients in over 50
therapeutic areas enables earlier identification of patients who
can benefit from enhanced treatment decision-making, risk
management, and quality.
Lana Ghanem, Managing Director of Hikma Ventures, said, "We are
excited to work with the highly qualified Prognos management team
that has extensive experience in both the healthcare and technology
industries. This investment is in line with our mission to focus on
the patient journey and help in early detection of disease. In
addition, we are enthusiastic about the expansion potential of this
technology both geographically and operationally."
"For Prognos, Series C is a focused and disciplined effort to
build on our success to scale the business as we pursue our mission
of predicting disease earlier to drive better outcomes for
patients," said Sundeep Bhan, Co-founder and CEO of Prognos. "We
are excited to be partnering with Hikma in exploring expansion
opportunities globally, especially in the Middle East and North
Africa, to deliver better patient care and lower costs."
-- ENDS --
Enquiries
Hikma Pharmaceuticals PLC
Lana Ghanem, Managing Director, +962(0)6 5802900/ +962
Hikma Ventures 79 8579391
Susan Ringdal, VP Corporate +44 (0)20 7399 2760/
Strategy and Investor Relations +44 7776 477050
FTI Consulting
Ben Atwell/ Brett Pollard +44 (0)20 3727 1000
About Hikma
Hikma Pharmaceuticals PLC is a multinational pharmaceutical
group focused on developing, manufacturing and marketing a broad
range of both branded and non-branded generic and in-licensed
products. Hikma's operations are conducted through three
businesses: 'Injectables,' 'Generics' and 'Branded,' based
primarily in the Middle East and North Africa (MENA) region, where
it is a market leader, the United States and Europe. In 2016, Hikma
achieved revenues of $1,950 million and profit attributable to
shareholders of $155 million.
About Hikma Ventures
Founded in August 2015, Hikma Ventures operates as the corporate
venture capital arm of Hikma Pharmaceuticals. Hikma Ventures
invests in global start-ups where Hikma's expertise can accelerate
revenue growth and enhance value creation by providing ventures
with access to the resources of a multinational pharmaceutical
company. For more information, visit www.hikmaventures.com
About Prognos
Prognos is a healthcare AI company focused on predicting disease
to drive decisions earlier in healthcare in collaboration with
payers, Life Sciences and diagnostics companies. The Prognos
Registry is the largest source of clinical diagnostics information
in 50 disease areas, with over 13B medical records for 180M
patients. Prognos has 1000 extensive proprietary and learning
clinical algorithms to enable earlier patient identification for
enhanced treatment decision-making, risk management and quality
improvement. For more information, visit www.prognos.ai
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAEAXFEDLKXFFF
(END) Dow Jones Newswires
November 30, 2017 12:47 ET (17:47 GMT)
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024